-
Lancet Haematol: Zebratinib is expected to be a new option for patients with B-cell malignancies who were previously intolerant to BTK
Time of Update: 2023-01-04
This is an ongoing, multicenter, open-label, single-arm Phase 2 clinical trial to evaluate whether zebratinib can prolong treatment in previously treated patients with B-cell malignancies by minimizing treatment-related toxicity and discontinuation.
-
Science Advances: Changes in cell behavior after neuroblastoma drug resistance
Time of Update: 2022-11-26
”essayClinically relevant treatment of the PDX model shows a pattern of chemoresistance in neuroblastoma Researchers at Lund University in Sweden have discovered one of the reasons why neuroblastomas in children become resistant to chemotherapy.
-
Lancet subjournal: Characteristics of circulating tumor DNA variation in aggressive breast lobular carcinoma
Time of Update: 2022-11-14
The researchers retrospectively analyzed data from 980 breast cancer patients with detailed clinical data (121 ILC, 972 IDC, and 62 mixed tissue types) and compared the single nucleotide variant (SNV), copy number variation (CNV) and oncogenic signaling pathway in the tissue samples.
-
How to achieve complete remission in patients with gastric cancer with multiple metastases
Time of Update: 2022-11-01
, Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report , World Journal of Surgical Oncology (2022) 20:289Click below to learn more about our clinical trial programsGastric cancer is a malignant tumor that occurs in the mucous membrane of the stomach, and cancer cells not only grow in the stomach wall, but also metastasize to other organs of the body through the blood and lymphatic system.
-
When advanced breast cancer is in remission, which treatment works
Time of Update: 2022-10-20
Results of PET-CT imaging before the first round of treatmentIn January 2019, after a few months of overall treatment, tests revealed that all of the patient's tumors had disappeared, doctors speculated that chemotherapy and targeted drugs worked, and it was unclear what role the cannabinoids and psilocybin played.
-
The immune system reacts fatally to the lungs
Time of Update: 2022-09-30
Caryl Boies, Professor Caryl Boies, and his team at Cold Spring Harbor Laboratory (CSHL), have identified a drug candidate that can prevent deadly lung inflammation in mice by inhibiting a protein called PTP1B.
-
The vaccine has not changed, why can the nine-valent HPV vaccine be expanded to 9-45 years old
Time of Update: 2022-09-07
” In this regard, the official website of the State Food and Drug Administration has clearly pointed out that the listing of the nine-valent HPV vaccine is based on the urgent clinical needs of drugs and the direct use of overseas clinical data for registration in China .
-
【WCLC】Broken cocoon and turned into a butterfly and reborn | Amivantamab combined with Lazertinib in the first-line treatment of patients with EGFR-sensitive mutation PFS may exceed 28 months
Time of Update: 2022-08-20
At present, the researchers are conducting a large-scale phase III study MARIPOSA to compare the efficacy and safety of the Amivantamab + Lazertinib regimen and the first-line treatment of osimertinib in patients with EGFR-sensitive mutated NSCLC, which is worth looking forward to .
-
Kite's CAR-T therapy approved by FDA for second-line treatment of lymphoma
Time of Update: 2022-04-27
S. Food and Drug Administration announced that it has approved the expanded scope of the CD19-targeted CAR-T therapy Yescarta (axicabtagene ciloleucel) developed by Kite Pharma, a subsidiary of Gilead Sciences, for the second-line treatment of large B-cell lymphoma (LBCL).
-
Professor Gu Yanhong: Multi-line chemotherapy for colorectal cancer failed, but immunotherapy achieved tumor remission and helped chronic disease management
Time of Update: 2022-04-26
Based on the results of its Phase II registration study, Nvolizumab was approved by the National Medical Products Administration (NMPA) of China on November 25 for the treatment of adult patients with advanced solid tumors with MSI-H/dMMR .
-
PeerJ: The risk of esophageal cancer can be 4 times worse by changing the type of fat intake
Time of Update: 2022-04-24
The association between MLC-SFA patterns and ESCC risk was different when stratified by fried foods ( I 2 = 75.
The association between MLC-SFA patterns and ESCC risk was different when stratified by fried foods ( I 2 = 75.
-
The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year
Time of Update: 2022-04-17
Today, Citius Pharmaceuticals announced positive top-line results from a pivotal Phase 3 clinical trial of its investigational therapy I/ONTAK (E7777) in patients with persistent or relapsed cutaneous T-cell lymphoma (CTCL) .
-
Adv Mater biomimetic lipoprotein system remodels tumor physical barrier and enhances T cell infiltration
Time of Update: 2022-03-09
Figure 1 S-LFO remodels the tumor stromal barrier and promotes T cell infiltrationFigure 2 S-LFO promotes intratumoral infiltration of CTLs Researcher Zhang Zhiwen and Li Yaping from Shanghai Institute of Materia Medica and Professor Wang Siling from Shenyang Pharmaceutical University are the co-corresponding authors of this article.
-
Front Immunol: Preliminary results of a propensity-matched trial of mycophenolate mofetil versus azathioprine in treatment-naïve AIH patients
Time of Update: 2022-03-05
As previous real-world studies and meta-analyses suggest that mycophenolate mofetil (MMF) may have better efficacy than azathioprine (AZA) in the treatment of autoimmune hepatitis (AIH), we conducted a propensity-matched study to evaluate MMF and the efficacy and safety of AZA .
-
CRISPR technology continues to advance hematopoietic stem cell therapy, focusing on sickle cell disease treatment
Time of Update: 2021-12-06
New Coronary Antibody Therapeutics Receives Positive Opinion from CHMPMedMeng broke the news November 20, 2021/MedClub News/--Next-generation gene editing company Graphite Bio recently announced that its gene-edited autologous hematopoietic stem cell therapy GPH 101 The first patient has been included in a phase 1/2 clinical trial.
